-+ 0.00%
-+ 0.00%
-+ 0.00%

Keybanc Maintains Overweight on NeuroPace, Lowers Price Target to $14

Benzinga·11/13/2026 13:51:36
Listen to the news
Keybanc analyst Brett Fishbin maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $18 to $14.